BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15107617)

  • 1. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
    Van Der Heijden MS; Brody JR; Kern SE
    Cancer Biol Ther; 2004 Jun; 3(6):534-7. PubMed ID: 15107617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
    van der Heijden MS; Brody JR; Gallmeier E; Cunningham SC; Dezentje DA; Shen D; Hruban RH; Kern SE
    Am J Pathol; 2004 Aug; 165(2):651-7. PubMed ID: 15277238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.
    Siddique MA; Nakanishi K; Taniguchi T; Grompe M; D'Andrea AD
    Exp Hematol; 2001 Dec; 29(12):1448-55. PubMed ID: 11750104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC.
    Taniguchi T; D'Andrea AD
    Blood; 2002 Oct; 100(7):2457-62. PubMed ID: 12239156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway.
    Gordon SM; Alon N; Buchwald M
    J Biol Chem; 2005 Oct; 280(43):36118-25. PubMed ID: 16127171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.
    Wilson JB; Johnson MA; Stuckert AP; Trueman KL; May S; Bryant PE; Meyn RE; D'Andrea AD; Jones NJ
    Carcinogenesis; 2001 Dec; 22(12):1939-46. PubMed ID: 11751423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
    Snyder ER; Ricker JL; Chen Z; Waes CV
    Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
    Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
    Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
    Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
    Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of Ubiquitination and Deubiquitination in the Fanconi Anemia Pathway.
    van Twest S; Murphy VJ; Hodson C; Tan W; Swuec P; O'Rourke JJ; Heierhorst J; Crismani W; Deans AJ
    Mol Cell; 2017 Jan; 65(2):247-259. PubMed ID: 27986371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
    Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
    Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.
    Taniguchi T; Garcia-Higuera I; Xu B; Andreassen PR; Gregory RC; Kim ST; Lane WS; Kastan MB; D'Andrea AD
    Cell; 2002 May; 109(4):459-72. PubMed ID: 12086603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathogenesis of fanconi anemia.
    Taniguchi T; Dandrea AD
    Int J Hematol; 2002 Feb; 75(2):123-8. PubMed ID: 11939257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel diagnostic screen for defects in the Fanconi anemia pathway.
    Shimamura A; Montes de Oca R; Svenson JL; Haining N; Moreau LA; Nathan DG; D'Andrea AD
    Blood; 2002 Dec; 100(13):4649-54. PubMed ID: 12393398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel ubiquitin ligase is deficient in Fanconi anemia.
    Meetei AR; de Winter JP; Medhurst AL; Wallisch M; Waisfisz Q; van de Vrugt HJ; Oostra AB; Yan Z; Ling C; Bishop CE; Hoatlin ME; Joenje H; Wang W
    Nat Genet; 2003 Oct; 35(2):165-70. PubMed ID: 12973351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation.
    Machida YJ; Machida Y; Chen Y; Gurtan AM; Kupfer GM; D'Andrea AD; Dutta A
    Mol Cell; 2006 Aug; 23(4):589-96. PubMed ID: 16916645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordination of the recruitment of the FANCD2 and PALB2 Fanconi anemia proteins by an ubiquitin signaling network.
    Bick G; Zhang F; Meetei AR; Andreassen PR
    Chromosoma; 2017 Jun; 126(3):417-430. PubMed ID: 27277787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Fanconi Anemia genes in familial breast cancer predisposition.
    Seal S; Barfoot R; Jayatilake H; Smith P; Renwick A; Bascombe L; McGuffog L; Evans DG; Eccles D; Easton DF; Stratton MR; Rahman N;
    Cancer Res; 2003 Dec; 63(24):8596-9. PubMed ID: 14695169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
    Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
    Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.